See Appendices [1](#hiv12411-app-0001){ref-type="app"} and [2](#hiv12411-app-0002){ref-type="app"}.

Introduction {#hiv12411-sec-0005}
============

One of the major challenges for children and young people with perinatal HIV infection is the maintenance of long‐term adherence to treatment regimens to suppress virus and prevent resistant virus from developing [1](#hiv12411-bib-0001){ref-type="ref"}. Paediatric HIV treatment regimens have relied heavily on drugs from one or more of the original three antiretroviral therapy (ART) classes \[nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs), non‐NRTIs (NNRTIs), and boosted protease inhibitors (bPIs)\], as drugs from newer classes often lack paediatric pharmacokinetic data and are not approved for use in children (e.g. rilpivirine, elvitegravir in \<18 years of age, dolutegravir in \< 12 years of age), or do not have appropriate paediatric formulations, and are often expensive [2](#hiv12411-bib-0002){ref-type="ref"}.

Current European guidelines recommend initiation of treatment in all infants aged \< 1 year, in children ≥ 1 year of age according to age‐specific immunological thresholds (1--3 years, CD4 count ≤ 1000 cells/μL or CD4% ≤ 25%; 3--5 years, CD4 count ≤ 750 cells/μL or CD4% ≤ 25%; \>5 years, CD4 count ≤ 350 cells/μL), and in any child with a World Health Organization (WHO) stage 3/4 or Centers for Disease Control and Prevention (CDC) category B/C event, largely to prevent progression to AIDS and death and to potentially optimize the ultimate CD4 count in adulthood [3](#hiv12411-bib-0003){ref-type="ref"}. In a previous study, we showed how the risk of triple‐class virological failure (TCVF) of the three original drug classes in children also increased with older age at the start of ART [4](#hiv12411-bib-0004){ref-type="ref"}. However, the main analysis of that study used a broad definition of TCVF which included now outdated treatment regimens, including unboosted PIs. A restricted analysis (including two NRTIs with either an NNRTI or a bPI) suggested that the overall rate of failure in children was over twice as high as in adults with heterosexually acquired HIV infection (hazard ratio 2.2; 95% confidence interval (CI) 1.6, 3.0; *P* \< 0.0001). Here we further explored the difference in TCVF rates between perinatally infected children and young adults aged 15 to 29 years with heterosexual infection, and in particular looked at the effect of age at the start of ART on risk of TCVF.

Methods {#hiv12411-sec-0006}
=======

Data were pooled from 22 cohort studies participating in the Pursuing Later Treatment Options II (PLATO II) project in 2010, which is part of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord ([www.cohere.org](http://www.cohere.org) and [www.eurocoord.net](http://www.eurocoord.net)), a collaboration of European cohort studies [5](#hiv12411-bib-0005){ref-type="ref"}. This study included 22 cohort studies with data on heterosexually infected adults aged 15--29 years, and five cohort studies with paediatric data on perinatally infected children and young people aged \< 20 years. We chose these age groups as we wished to compare perinatally HIV‐infected children and teenagers with adults with horizontal infection who were of a similar age group, and to show how the risk of TCVF differs across this age spectrum. A comparison of younger and older age groups has already been published elsewhere [6](#hiv12411-bib-0006){ref-type="ref"}. The cohort studies included diagnosed HIV‐infected patients attending treatment services across Europe, collecting similar data items. Data submission and quality control procedures have been described previously [5](#hiv12411-bib-0005){ref-type="ref"}.

Participants were antiretroviral‐naïve or had previous ART exposure for prevention of mother‐to‐child transmission (PMTCT), and started ART from 1998 onwards with an initial regimen of two or more NRTIs and either an NNRTI or a bPI. Follow‐up time began at the start of ART and data were censored at the last reported viral load measurement. Because the definition of virological failure used in this study required 4 months of use of a drug, children were only included if they had at least 4 months (122 days) of follow‐up. Time spent off ART (after ART had been started) was included as follow‐up. Participants were said to be off ART if they stopped all antiretroviral drugs. Treatment interruption was defined as cessation of all antiretrovirals for at least 7 days.

The main outcome measure was time to TCVF, defined as virological failure of at least two NRTI drugs, one NNRTI drug, and one bPI drug. Virological failure of a drug was defined as one viral load \> 500 HIV‐1 RNA copies/mL following at least 4 months of continuous use of that drug, regardless of concomitant use of other drugs in that period. Sensitivity analyses were conducted using two variations of this virological failure definition: first, 6 months instead of 4 months of continuous drug use; secondly, viral load \> 500 copies/mL after 4 months of continuous use had to be confirmed by a second viral load \> 500 copies/mL while still on the drug or followed by discontinuation of the drug.

The date of the first HIV clinic visit was calculated as the earliest date of: first CD4 count, first viral load measurement, first visit, first diagnosis of an AIDS‐defining condition, or start of ART (including ART for PMTCT).

Kaplan−Meier and Cox regression methods were used to investigate the risk of TCVF after starting ART. Potential predictors of TCVF at the time of starting ART were sex, age group/risk group, region of origin, year of starting ART, initial regimen, previous ART exposure for PMTCT, pre‐ART AIDS diagnosis, CD4 (a binary measure combining CD4% \<= 25% for patients \<5 years of age and CD4 count \<= 350 cells/μL for patients ≥5 years of age), and viral load (a binary measure, above or below the median viral load within each age group). In multivariable analyses, perinatally HIV‐infected young people aged 15--19 years at the start of ART were excluded because of their small number (*n* = 20) and lack of TCVF events. HIV‐related outcomes for those experiencing TCVF are described.

Analyses were performed using [sas]{.smallcaps} software, version 9.3 (SAS Inc., Cary, NC).

Results {#hiv12411-sec-0007}
=======

A total of 5972 participants fulfilling the inclusion criteria were identified, and their characteristics at the start of ART by risk group and age are summarized in Table [1](#hiv12411-tbl-0001){ref-type="table-wrap"}. Overall, 806 participants (13%) had perinatally acquired HIV infection, and started ART aged \< 20 years, and 5166 participants (87%) acquired HIV heterosexually and started ART aged 15--29 years. In the 15--19 years age category, 20 (7%) had perinatally acquired HIV infection and 264 (93%) had heterosexually acquired HIV infection, while all those \< 15 years of age had perinatally acquired HIV infection, and all those ≥ 20 years of age had acquired HIV heterosexually. Initial regimens included lopinavir/r for 26% of participants with heterosexually acquired HIV infection and 17% of those with perinatally acquired HIV infection, efavirenz for 34% of those with heterosexually acquired HIV infection and 37% of those with perinatally acquired HIV infection, and nevirapine for 26% of those with heterosexually acquired HIV infection and 46% of those with perinatally acquired HIV infection.

###### 

Characteristics of the 5972 included participants at the start of antiretroviral therapy (ART)

  Characteristic                                              Risk group                                                                                                               
  ----------------------------------------------------------- ------------------ ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ----------------
  Number (%) of participants                                  238 (4)            148 (2)          229 (4)          171 (3)          20 (\<1)         264 (4)          1459 (24)        3443 (58)
  Sex \[*n* (%)\]                                                                                                                                                                      
  Male                                                        101 (42)           83 (56)          119 (52)         79 (46)          6 (30)           58 (22)          319 (22)         946 (27)
  Female                                                      137 (58)           65 (44)          110 (48)         92 (54)          14 (70)          206 (78)         1140 (78)        2497 (73)
  Region of origin \[*n* (%)\]                                                                                                                                                         
  Sub‐Saharan Africa                                          57 (24)            75 (51)          153 (67)         112 (65)         15 (75)          103 (39)         459 (31)         902 (26)
  Europe                                                      169 (71)           61 (41)          62 (27)          50 (29)          5 (25)           35 (13)          277 (19)         708 (21)
  Other                                                       11 (5)             12 (8)           13 (6)           8 (5)            0 (0)            6 (10)           195 (13)         536 (16)
  Unknown                                                     1 (\<1)            0 (0)            1 (\<1)          1 (1)            0 (0)            100 (38)         528 (36)         1297 (38)
  Pre‐ART AIDS \[*n* (%)\]                                                                                                                                                             
  Yes                                                         69 (29)            27 (18)          30 (13)          21 (12)          1 (5)            38 (14)          174 (12)         501 (15)
  Time from diagnosis to ART start (weeks) \[median (IQR)\]   6 (2--18)          24 (5--102)      41 (5--185)      49 (9--267)      176 (55--404)    6 (1--19)        7 (2--33)        8 (2--44)
  CD4 count                                                                                                                                                                            
  Median (IQR) (cells/μL)                                     1170 (490--1818)   510 (279--793)   281 (160--482)   190 (94--286)    181 (89--231)    262 (163--395)   252 (155--375)   226 (125--325)
  Missing \[*n* (%)\]                                         79 (33)            21 (14)          41 (18)          28 (16)          4 (20)           38 (14)          199 (14)         466 (14)
  CD4 percentage                                                                                                                                                                       
  Median (IQR)                                                25 (15--33)        14 (10--19)      13 (9--18)       12 (6--17)       --               --               --               --
  Missing \[*n* (%)\]                                         81 (34)            20 (14)          48 (21)          31 (18)                                                             
  Viral load                                                                                                                                                                           
  Median (IQR) (log~10~ copies/mL)                            5.7 (5.0--5.9)     5.1 (4.7--5.6)   5.0 (4.6--5.3)   4.8 (4.2--5.2)   4.5 (4.2--4.8)   4.8 (3.9--5.2)   4.6 (4.0--5.0)   4.6 (4.0--5.1)
  Missing \[*n* (%)\]                                         67 (28)            19 (13)          49 (21)          25 (15)          2 (10)           44 (17)          208 (14)         509 (15)
  Year of starting ART \[*n* (%)\]                                                                                                                                                     
  1998--2000                                                  43 (18)            31 (21)          28 (12)          15 (9)           2 (10)           33 (13)          232 (16)         565 (16)
  2001--2003                                                  81 (34)            51 (34)          81 (35)          43 (25)          1 (5)            90 (34)          416 (29)         1018 (30)
  2004--2006                                                  79 (33)            48 (32)          91 (40)          74 (43)          9 (45)           106 (40)         548 (38)         1261 (37)
  2007--2009                                                  35 (15)            18 (12)          29 (13)          39 (23)          8 (40)           35 (13)          263 (18)         599 (17)
  Initial regimen \[*n* (%)\]                                                                                                                                                          
  NNRTI + ≥ 2 NRTIs                                           175 (74)           126 (85)         200 (87)         150 (88)         15 (75)          150 (57)         833 (57)         2107 (61)
  bPI + ≥ 2 NRTIs                                             63 (26)            22 (15)          29 (13)          21 (12)          5 (25)           114 (43)         626 (43)         1336 (39)
  PMTCT \[*n* (%)\]                                                                                                                                                                    
  Yes                                                         53 (22)            7 (5)            1 (\< 1)         --               --               --               --               --

bPI, boosted protease inhibitor; IQR, interquartile range; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PMTCT, prevention of mother‐to‐child transmission.
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Around half of participants with perinatally acquired HIV infection and three‐quarters of those with heterosexually acquired HIV infection were female, and the majority of most age groups were from sub‐Saharan Africa. In participants with perinatal HIV infection, the median age when first seen was 0.5 years \[interquartile range (IQR) 0.0--2.7 years\] for those born in Europe compared with 5.9 years (IQR 2.4--9.4 years) for those from sub‐Saharan Africa. The median duration between date first seen and the start of ART varied by risk group and age. It was around 6‐8 weeks for infants with perinatal HIV infection and participants who acquired HIV infection heterosexually, but much longer for children with perinatal HIV infection starting ART at age 5--9 years and 10--14 years \[median 41 (IQR 5--185) and 49 (IQR 9--267) weeks, respectively\], and highest in participants with perinatal HIV infection starting ART at age 15--19 years, although numbers were small \[median 176 (IQR 55--404); *n* = 20\] (Table S1).

Median CD4 cell count at the start of ART was lower in participants with perinatal HIV infection aged 10--14 and 15--19 years than in participants who acquired HIV heterosexually and also younger patients with perinatal HIV infection, and, as expected, the median CD4 percentage was higher in infants than in other perinatally infected groups. Similarly, viral load was highest in perinatally infected infants, and lowest at around 4.6 log~10~ copies/mL in all patients aged ≥ 10 years. Most participants started ART between 2000 and 2006. The vast majority (83%) of patients with perinatal HIV infection and 60% of those who acquired HIV heterosexually started on an NNRTI‐based regimen.

The overall median follow‐up from the start of ART was 3.5 (IQR 1.7--5.9) years. The median duration of follow‐up was markedly lower for participants with perinatal HIV infection aged 15--19 years \[1.4 (IQR 1.0--2.3) years\]. The rate (95% CI) of treatment interruption was 7.4 (6.5--8.4) per 100 person‐years in participants with perinatal HIV infection and 9.8 (9.4--10.3) per 100 person‐years in adults who had acquired HIV heterosexually. In those who had interrupted treatment, the rate (95% CI) of restarting was 67.4 (57.2--78.9) per 100 person‐years in participants with perinatal HIV infection and 56.4 (53.5--59.5) per 100 person‐years in those with heterosexually acquired HIV.

Just under half (357) of participants with perinatal HIV infection and 1774 of those who acquired HIV heterosexually experienced virological failure. By 5 years after starting ART, 49.9% (95% CI 45.8−54.0%) and 41.2% (95% CI 39.5−42.8%), respectively, had experienced virological failure, with no marked differences by age group (Table S1). By the end of follow‐up, 216 of 806 patients with perinatal HIV infection and 1539 of 5166 patients with heterosexually acquired HIV had started a third drug class, and 70 with perinatal HIV infection and 182 with heterosexually acquired HIV had developed TCVF. The cumulative proportion of participants experiencing TCVF by age at the start of ART and risk group is shown in Table [2](#hiv12411-tbl-0002){ref-type="table-wrap"} and Figure [1](#hiv12411-fig-0001){ref-type="fig"}, and was higher in patients with perinatal HIV infection compared with those with heterosexually acquired HIV overall, and was particularly high in perinatally infected participants aged 10--14 years, at 27.7% (95% CI 13.2--42.1) by 5 years (Table S1). Of the 252 patients overall with TCVF, 12 (4.8%) had never attained a viral load ≤ 500 copies/mL.

###### 

Participants developing triple‐class virological failure (TCVF): number, proportion, and predictors from univariable and multivariable Cox models

                                                                                 Estimated cumulative proportion developing TCVF by 5 years (%)[b](#hiv12411-note-0006){ref-type="fn"}   Univariable results   Multivariable results                                        
  ------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------- --------------------- ----------------------- ---------- ------------ ------------ ----------
  Sex                                                                                                                                                                                                                                                                       
  Male                                                                           6.9 (5.2--8.5)                                                                                          1                     --                      0.0055     1            --           0.17
  Female                                                                         4.9 (3.9--5.8)                                                                                          0.70                  0.54--0.90              0.83       0.64--1.09                
  Age at start of ART and risk group                                                                                                                                                                                                                                        
  \< 2 years; perinatally acquired                                               7.8 (3.7--12.0)                                                                                         1.83                  1.11--3.00              \<0.0001   2.16         1.25--3.72   \<0.0001
  2--4 years; perinatally acquired                                               4.5 (0.6--8.5)                                                                                          1.67                  0.90--3.09              1.45       0.76--2.75                
  5--9 years; perinatally acquired                                               8.4 (3.9--12.9)                                                                                         2.49                  1.56--3.96              1.96       1.18--3.25                
  10--14 years; perinatally acquired                                             27.7 (13.2--42.1)                                                                                       6.16                  3.81--9.97              5.19       3.11--8.65                
  15--19 years; heterosexually acquired[a](#hiv12411-note-0005){ref-type="fn"}   2.1 (0.0--4.1)                                                                                          0.84                  0.39--1.80              0.76       0.36--1.65                
  20--24 years; heterosexually acquired                                          5.8 (4.0--7.6)                                                                                          1.34                  0.98--1.82              1.36       0.99--1.85                
  25--29 years; heterosexually acquired                                          4.5 (3.5--5.4)                                                                                          1                     --                      1          --                        
  Region of origin                                                                                                                                                                                                                                                          
  Sub‐Saharan Africa                                                             6.8 (5.2--8.5)                                                                                          1                     --                      0.0003     1            --           0.012
  Europe                                                                         4.5 (3.0--6.0)                                                                                          0.56                  0.40--0.79              0.59       0.41--0.84                
  Other/unknown                                                                  5.1 (3.9--6.3)                                                                                          0.61                  0.46--0.81              0.79       0.58--1.08                
  Pre‐ART AIDS                                                                                                                                                                                                                                                              
  No                                                                             4.9 (4.0--5.7)                                                                                          1                                             0.0044     1            --           0.039
  Yes                                                                            8.5 (6.1--11.0)                                                                                         1.55                  1.15--2.08              1.38       1.02--1.88                
  Initial regimen                                                                                                                                                                                                                                                           
  NNRTI + ≥2 NRTIs                                                               6.1 (5.1--7.1)                                                                                          1                     --                      0.0011     1            --           0.0023
  bPI + ≥2 NRTIs                                                                 3.9 (2.5--5.3)                                                                                          0.58                  0.42--0.80              0.59       0.42--0.83                
  Pre‐ART CD4 composite measure[c](#hiv12411-note-0007){ref-type="fn"}                                                                                                                                                                                                      
  CD4% \< 25%/CD4 \< 350 cells/μL                                                6.3 (5.2--7.4)                                                                                          1                     --                      0.044      1            --           0.009
  CD4% ≥ 25%/CD4 ≥ 350 cells/μL                                                  3.8 (2.3--5.3)                                                                                          0.74                  0.53--1.03              0.85       0.60--1.20                
  Unknown                                                                        4.4 (2.6--6.1)                                                                                          0.68                  0.47--0.99              0.48       0.29--0.77                
  Pre‐ART viral load                                                                                                                                                                                                                                                        
  Below median for age group                                                     3.3 (2.3--4.3)                                                                                          1                     --                      0.0018     1            --           0.0005
  Above median for age group                                                     7.0 (5.6--8.3)                                                                                          1.67                  1.26--2.22              1.66       1.24--2.22                
  Unknown                                                                        6.6 (4.4--8.7)                                                                                          1.47                  1.01--2.14              2.13       1.34--3.40                

ART, antiretroviral therapy; bPI, boosted protease inhibitor; CI, confidence interval; HR, hazard ratio; IQR, interquartile range; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor.

Year of starting ART (unadjusted *P* = 0.43), previous ART exposure for prevention of mother‐to‐child transmission (unadjusted *P* = 0.083) and sex (adjusted *P* = 0.09) were all not significant.

For the age group 15--19 years, data are shown for participants with heterosexually acquired HIV infection only, as there were only 20 participants and no events in the 15‐19‐year age group for participants with perinatally acquired HIV infection.

Kaplan−Meier estimates (95% confidence intervals).

CD4% for \< 5 years; CD4 count for ≥ 5 years.
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![Kaplan−Meier plots showing the cumulative proportion of participants experiencing triple‐class virological failure (TCVF) by age at the start of antiretroviral therapy (ART) and risk group.](HIV-18-171-g001){#hiv12411-fig-0001}

In a multivariable model (Table [2](#hiv12411-tbl-0002){ref-type="table-wrap"}), after adjustment for other factors, there was a strong association between age group and risk group and risk of TCVF. Participants with perinatal HIV infection aged 10--14 years at ART initiation had a markedly raised risk of failure \[hazard ratio (HR) 5.19; 95% CI 3.11--8.65\], participants with perinatal HIV infection aged \< 10 years had an increased risk (e.g. 5--9 years: HR 1.96; 95% CI 1.18--3.25), and those with heterosexually acquired HIV aged 15--19 years (HR 0.76; 95% CI 0.36--1.65) and 20--24 years (HR 1.36; 95% CI 0.99--1.85) had a similar risk, compared with those with heterosexually acquired HIV infection aged 25--29 years. Additionally, participants originating from Europe compared with sub‐Saharan Africa and those starting bPI regimens compared with NNRTI regimens had a lower risk, and those with an AIDS diagnosis before starting ART had a higher risk, as did those with a higher pre‐ART viral load and lower pre‐ART CD4. There was no difference in the risk of failure by sex, ART exposure for PMTCT in infancy, or year of ART initiation. Sensitivity analyses conducted using two variations of the virological failure definition produced similar results, including in patients \< 2 years of age with perinatal infection.

Clinical outcomes following TCVF are shown in Table S2. Overall, 1 year after TCVF, CD4 counts were higher in younger participants with perinatally acquired HIV infection and those with heterosexually acquired HIV infection than in participants with perinatal HIV infection aged 10--14 years, although numbers were small. Similarly, median viral load was higher in perinatally infected participants aged 10--14 years and lower in all other participant groups. Five per cent (three of 64) of participants with perinatal HIV infection with follow‐up data available after TCVF had been diagnosed with AIDS or died, compared with 11% (19 of 170) of participants with heterosexually acquired HIV infection; 9% (six of 64) of perinatally infected participants compared with 25% (43 of 170) of those with heterosexually acquired HIV infection had started at least one new drug by 1 year following TCVF.

Discussion {#hiv12411-sec-0008}
==========

In this large collaborative study in which the risk of TCVF from the start of ART in perinatally HIV‐infected children was directly compared with that in adults with heterosexually acquired HIV infection, 4.2% developed TCVF overall. The highest risk of TCVF was in 10‐14‐year‐old participants with perinatal infection; for this group, the cumulative incidence of TCVF by 3 years was nearly 10%, rising sharply to just under 30% by 5 years, while in all other age groups the proportion at 5 years was \< 9%. This trend was shown in the multivariable analysis in which the rate of failure in this group was five times higher than in adults aged 25--29 years with heterosexually transmitted HIV infection. These results augment those of our earlier study which described the rate and predictors of TCVF in children, and which presented only a very simple analysis comparing rates between children and adults [4](#hiv12411-bib-0004){ref-type="ref"}. Here, we estimated the differing rates of TCVF across the age spectrum from infants to young adults, as well as by transmission group.

Participants with perinatally acquired HIV infection aged 10--14 years had not only the highest rate of TCVF but also the longest delay in starting ART following HIV diagnosis, and the lowest CD4 counts at the start of ART. Many of these young people were born in sub‐Saharan Africa, some without access to antenatal testing; they may have complex family issues with a high proportion being orphans, and HIV symptoms may not have been recognized, leading to delayed diagnosis [7](#hiv12411-bib-0007){ref-type="ref"}, [8](#hiv12411-bib-0008){ref-type="ref"}. Some will have insecure immigration status which can intensify concerns about HIV diagnosis and treatment, and disclosure of HIV infection in the family [9](#hiv12411-bib-0009){ref-type="ref"}, [10](#hiv12411-bib-0010){ref-type="ref"}. There can also be issues of coming to terms with their own HIV status, secrecy and guilt among other family members, and dealing with HIV infection in the context of the adolescent transitional stage of development [11](#hiv12411-bib-0011){ref-type="ref"}, [12](#hiv12411-bib-0012){ref-type="ref"}. Once ART has been started, studies have found lower rates of viral suppression in young people with perinatal HIV infection compared with adults [13](#hiv12411-bib-0013){ref-type="ref"}, which are probably attributable to adherence issues and poor clinic attendance rather than drug efficacy, both common problems among young adults living with other chronic diseases [1](#hiv12411-bib-0001){ref-type="ref"}, [14](#hiv12411-bib-0014){ref-type="ref"}, [15](#hiv12411-bib-0015){ref-type="ref"}, [16](#hiv12411-bib-0016){ref-type="ref"}. Findings from this study support the benefit of earlier age at diagnosis where possible, and initiation of ART prior to the adolescent period, which will probably also favour improved immunological health [17](#hiv12411-bib-0017){ref-type="ref"}.

In this study, most participants with perinatal HIV infection started on an NNRTI‐based regimen, while two‐fifths of participants with heterosexually acquired infection in the study started on bPIs, and those starting with bPI‐based regimens were less likely to develop TCVF. In our previous study with resistance test data, we found that most children on an NNRTI regimen had resistance mutations, but PI resistance was not seen [4](#hiv12411-bib-0004){ref-type="ref"}. Resistance results from the PENPACT‐1 trial showed that delaying switching for those starting a PI‐based regimen was a reasonable strategy, but that more rapid switching from an NNRTI‐based regimen following virological failure was needed to avoid accumulation of NRTI resistance mutations [18](#hiv12411-bib-0018){ref-type="ref"}; in this study, these findings would mean that a higher proportion of the NNRTI group would be at risk of TCVF. However, results from a large adult trial of second‐line treatment following NNRTI‐based first‐line therapy suggested that participants given a PI as second‐line therapy retained NRTI virological activity without evidence of increased toxicity, even in the presence of NRTI resistance mutations [19](#hiv12411-bib-0019){ref-type="ref"}, suggesting that, although in our study participants met the criteria of TCVF, its impact may not be substantial.

European guidelines now recommend that if adherence is questionable, as is often seen in teenagers, a PI‐based regimen should be initiated because of its higher genetic barrier to resistance [3](#hiv12411-bib-0003){ref-type="ref"}, [20](#hiv12411-bib-0020){ref-type="ref"}. Many of the participants with perinatal HIV infection on PI‐based regimens in our study would have been on lopinavir/r regimens, which are unpopular among adolescents as they require twice‐daily administration, but now both darunavir and atazanavir are available to adolescents in once‐daily formulations and have better tolerability. Furthermore, two new once‐daily single‐tablet regimens combining integrase inhibitors with an NRTI backbone have recently been licensed for adults and children aged 12 years and older weighing at least 35--40 kg and may become a suitable alternative to PI‐based regimens for adolescents [21](#hiv12411-bib-0021){ref-type="ref"}, [22](#hiv12411-bib-0022){ref-type="ref"}, [23](#hiv12411-bib-0023){ref-type="ref"}, [24](#hiv12411-bib-0024){ref-type="ref"}, [25](#hiv12411-bib-0025){ref-type="ref"}. Similarly, innovative treatment strategies designed to improve adherence are needed for adolescents, and the phase II BREaks in Adolescent and child THerapy using Efavirenz and two nRtis (BREATHER) trial recently reported noninferiority of virological suppression in young people on efavirenz plus two NRTIs having weekends off compared with continuous therapy; long‐term follow‐up of these trial participants has begun [26](#hiv12411-bib-0026){ref-type="ref"}.

In conclusion, for participants with perinatal HIV infection, these findings indicate the need to diagnose and start ART earlier in childhood, and adopt a strategic approach in ART selection to prevent the emergence of resistance. These measures may help children and adolescents achieve and sustain virological suppression as they approach adulthood.
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